Celldex Therapeutics, Inc. Stock

Equities

CLDX

US15117B2025

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:37:56 2024-04-17 pm EDT 5-day change 1st Jan Change
39.94 USD +3.46% Intraday chart for Celldex Therapeutics, Inc. +2.02% +0.81%
Sales 2024 * 3.39M Sales 2025 * 3.13M Capitalization 2.49B
Net income 2024 * -170M Net income 2025 * -203M EV / Sales 2024 * 650 x
Net cash position 2024 * 285M Net cash position 2025 * 372M EV / Sales 2025 * 676 x
P/E ratio 2024 *
-13.3 x
P/E ratio 2025 *
-11.9 x
Employees 160
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.65%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Celldex Therapeutics, Inc.

1 day+1.41%
1 week-1.02%
Current month-7.58%
1 month-5.30%
3 months-2.32%
6 months+57.55%
Current year-2.19%
More quotes
1 week
38.14
Extreme 38.14
41.67
1 month
38.10
Extreme 38.1
43.42
Current year
34.65
Extreme 34.65
53.18
1 year
22.11
Extreme 22.11
53.18
3 years
19.85
Extreme 19.85
57.20
5 years
1.50
Extreme 1.5
57.20
10 years
1.50
Extreme 1.5
492.30
More quotes
Managers TitleAgeSince
Founder 65 82-12-31
Founder 62 82-12-31
Director of Finance/CFO 53 09-03-31
Members of the board TitleAgeSince
Director/Board Member 91 08-02-29
Director/Board Member 58 22-06-15
Director/Board Member 78 96-12-31
More insiders
Date Price Change Volume
24-04-17 39.98 +3.58% 346 146
24-04-16 38.6 -1.20% 722,557
24-04-15 39.07 -0.46% 409,378
24-04-12 39.25 -3.96% 498,039
24-04-11 40.87 +4.29% 595,686

Delayed Quote Nasdaq, April 17, 2024 at 09:50 am EDT

More quotes
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
38.6 USD
Average target price
70.71 USD
Spread / Average Target
+83.20%
Consensus